Drug Search Results

Perifosine

Alternative Names: perifosine
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Akt Inhibitor,PI3K Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AEterna Zentaris
Company Location: MONTREAL A8 H3B 3V2
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Perifosine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Multiple Myeloma|Colorectal Cancer

Phase 2: Prostate Cancer|Sarcoma|Waldenstrom Macroglobulinemia|Endometrial Cancer|Leukemia|Breast Cancer|Adenocarcinoma|Chronic Lymphoid Leukemia|Colorectal Cancer|Lymphocytic Chronic B-Cell Leukemia|Kidney Cancer|Melanoma|Lymphoma, B-Cell|Ovarian Cancer|Multiple Myeloma|Pancreatic Cancer|Renal Cell Carcinoma|Oligodendroglioma|Astrocytoma|Glioblastoma|Gliosarcoma|Cervical Cancer|Head and Neck Cancer|Brain Cancer|Lymphoma|Non-Small-Cell Lung Cancer|Glioma|Chondrosarcoma|Alveolar Soft Part Sarcoma|Gastrointestinal Stromal Tumors

Phase 1: Hypertrophy, Left Ventricular|Angina, Unstable|Hypokalemia|Multiple Myeloma|Prostate Cancer|Oncology Solid Tumor Unspecified|Colorectal Cancer|Diarrhea|Renal Cell Carcinoma|Liver Cancer|Kidney Cancer|Acute Lymphoid Leukemia|Preleukemia|Acute Megakaryoblastic Leukemia|Acute Erythroblastic Leukemia|Myelodysplastic Syndrome|Myelodysplastic-Myeloproliferative Diseases|Chronic Myelomonocytic Leukemia|Acute Monocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Contraception|Surgical Wound Infection|Lymphoma|Angina Pectoris|Myocardial Infarction|Pregnancy Outcomes|Chronic Lymphoid Leukemia|Hepatitis B, Chronic|Hepatitis C, Chronic|Neuroblastoma|Neuromyelitis Optica|Blast Crisis|Myeloproliferative Disorders|Angina, Stable|Heart Failure, Chronic|Heart Failure, Acute|HIV Infections|Torsades de Pointes|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Chronic Myeloid Leukemia|Acute Promyelocytic Leukemia|Adult T-Cell Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Myeloid, Accelerated Leukemia|Ovarian Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Astrocytoma|Brain Cancer|Oligodendroglioma|Glioblastoma

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
NCT00590954	P2	Completed	Brain Cancer\|Glioma	2019-11-11
NCI-2011-01409	P2	Completed	Gliosarcoma\|Oligodendroglioma\|Glioblastoma\|Astrocytoma	2018-11-16
AAAM3801	P1	Completed	Brain Cancer\|Astrocytoma\|Oligodendroglioma\|Glioblastoma	2017-10-27
NCT00776867	P1	Completed	Oncology Solid Tumor Unspecified	2017-07-01

Recent News Events

Date	Type	Title
03/01/2024	PubMed	Neuroprotective effects of Rehmannia glutinosa polysaccharide on chronic constant light (CCL)-induced oxidative stress and autophagic cell death via the AKT/mTOR pathway in mouse hippocampus and HT-22 cells.
02/01/2024	PubMed	Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells.
01/15/2024	PubMed	ROS/mtROS promotes TNTs formation via the PI3K/AKT/mTOR pathway to protect against mitochondrial damages in glial cells induced by engineered nanomaterials.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions